Use of ALA and ALA derivatives for optimizing ALA-based photodynamic therapy: a review of our experience.
5-Aminolevulinic acid (ALA)-based PDT has been gaining increased attention in the last ten years, and become an approved treatment modality for some cancers and other diseases. Different approaches to enhance this therapeutic modality are in progress, including the development of several drug delivery systems and the use of more lipophilic ALA derivatives. This paper focuses on our experience in this field.
Centro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), CONICET and University of Buenos Aires, Viamonte 188110A, 1056 Buenos Aires, Argentina.
Haydee
H
Fukuda
Adriana
A
Casas
Alcira
A
Batlle
D000622:Aminolevulinic Acid / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D004950:Esterases / Q000378:metabolism; D006418:Heme / Q000096:biosynthesis; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D010778:Photochemotherapy; D017319:Photosensitizing Agents; D011355:Prodrugs / Q000494:pharmacology; D011524:Protoporphyrins / Q000378:metabolism
D017319:Photosensitizing Agents; D011355:Prodrugs; D011524:Protoporphyrins; D006418:Heme; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX; D004950:Esterases